Healthcare & Life Sciences Investors
Lanton, Lanton & Sosa Law, PLLC advises venture capital firms, private equity investors, investment banks, family offices, healthcare lenders, strategic investors and portfolio companies. Our Boston and Washington, D.C. attorneys examine healthcare regulatory and commercial risks in acquisitions, investments and financings.
Legal and Regulatory Due Diligence
Healthcare regulatory diligence: Review of licenses, healthcare fraud and abuse exposure, pharmacy operations and material contracts.
Pharmaceutical pricing, reimbursement and market access: Counsel on Medicare and Medicaid reimbursement, PBM contracting, 340B, drug pricing and market access policy.
Life sciences commercialization: Review of licensing, collaboration, distribution, commercialization and supply agreements for pharmaceutical and biotechnology companies.
Healthcare mergers and acquisitions: Targeted due diligence, contractual risk assessment and transaction structuring alongside deal counsel.
Digital health and artificial intelligence: Commercial agreements, technology licensing, data use, AI governance and healthcare regulatory diligence.
Policy and legislative risk: Analysis of legislation and agency action that may affect reimbursement, market entry or a target company’s business model.
Investor, Lender and Portfolio Company Counsel
We work with law firms, in-house legal teams, transaction teams, investment banking and equity research teams seeking healthcare legal and regulatory analysis. We also offer outside general counsel services for portfolio companies. Our services are legal and regulatory in nature, not securities brokerage or investment recommendations.
Healthcare Investor Briefing
Explore our Insights for analysis of healthcare policy, pricing, reimbursement and commercialization.
Contact LL&S to discuss investor counsel, transaction diligence or regulatory co-counsel services.